Wed | Jul 8, 2026

Merck asks EU regulator to authorise pill that treats COVID

Published:Tuesday | October 26, 2021 | 1:27 PM
This undated image provided by Merck & Co. shows their new antiviral medication. Pharmaceutical company Merck & Co. said Friday, October 1, 2021, that its experimental COVID-19 pill reduced hospitalisations and deaths by half in people recently infected with the coronavirus and that it would soon ask health officials in the US and around the world to authorise its use. (Merck & Co. via AP)

AMSTERDAM (AP) — The pharmaceutical company Merck says it has asked the European Medicines Agency to authorise its COVID-19 antiviral treatment, the first pill that has been shown to treat the disease.

In a statement on Monday, Merck said the EU drug regulator had started an expedited licensing process for molnupiravir.

If given the green light, it would be the first treatment for COVID-19 that does not need to be administered through needles or intravenous infusions.

Earlier this month, Merck asked the US Food and Drug Administration to OK molnupiravir, and a decision is expected within weeks.

The company reported this month that the pill cut hospitalisations and deaths by half among patients with early symptoms of COVID-19.

The results were so strong that independent medical experts monitoring the trial recommended stopping it early.

An antiviral pill that people could take at home to reduce their symptoms and speed recovery could prove groundbreaking, easing the crushing caseload on hospitals and helping to curb outbreaks in poorer countries with weak health care systems.

It would also bolster a two-pronged approach to the pandemic: treatment, by way of medication, and prevention, primarily through vaccinations.

Follow The Gleaner on Twitter and Instagram @JamaicaGleaner and on Facebook @GleanerJamaica. Send us a message on WhatsApp at 1-876-499-0169 or email us at onlinefeedback@gleanerjm.com or editors@gleanerjm.com.